[Case Study] Keisuke Kagami and Mitsuru Sugawara “Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.” (AMR Alliance Japan, February 22, 2022)
date : 2/22/2022
Tags: AMR
As part of the Alliance’s project to promote antimicrobial steward among medical professionals, AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) has begun publishing case studies from various experts related to antimicrobial resistance.
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital) and Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University) reports a case titled “Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.”
In this study, the usefulness of TDM (Therapeutic Drug Monitoring) for antimicrobial stewardship is reported.
Case study 05
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital)
Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
“Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.”
For further information, please see the case study below.
Case study 01
Dr. Keiji Okinaka (Director of Infection Control and Prevention Section, National Cancer Center Hospital East / Department of General Internal Medicine, National Cancer Center Hospital East /Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)
“A disseminated filamentous fungal infection that broke through echinocandin antifungal treatment”
Case study 04
Dr. Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital)
“The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”
Top Research & Recommendations Posts
- [Research Report] Perceptions, Knowledge, Actions and Perspectives of Healthcare Organizations in Japan in Relation to Climate Change and Health: A Cross-Sectional Study (November 13, 2025)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Research Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Final Version) (November 14, 2024)
- [Policy Recommendations] Mental Health Project: Recommendations on Three Issues in the Area of Mental Health (July 4, 2025)
- [Policy Recommendations] Reshaping Japan’s Immunization Policy for Life Course Coverage and Vaccine Equity: Challenges and Prospects for an Era of Prevention and Health Promotion (April 25, 2025)
- [Publication Report] Planetary Health Promotion Project “Issues Facing Planetary Health and the Role of the Health Sector” (May 10, 2023)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Announcement] HGPI Joins Global Green and Healthy Hospitals (August 1, 2023)
Featured Posts
-
2025-11-13
[Registration Open] (Webinar) The 1st J-PEP Seminar – Initiating Policy Advocacy from Meaningful Involvement (December 8, 2025)
-
2025-12-01
[Policy Recommendations] Recommendations on Strategic Investments in Policies for Brain Health to Revitalize Japan: Hopes for the New Administration (December 1, 2025)



